NasdaqGM:ARDXBiotechs
Ardelyx (ARDX): Revisiting Valuation After a Strong Multi‑Year Shareholder Return Run
Ardelyx (ARDX) has quietly outperformed many small-cap biotechs this year, and its mix of rising revenue and shrinking losses is drawing fresh attention from investors who are watching the company’s recent business trends.
See our latest analysis for Ardelyx.
At its latest share price of $5.68, Ardelyx has had a choppy few months, with a 30 day share price return of 4.8 percent but a 90 day share price return of negative 8.7 percent. Its 1 year total shareholder return of 17.8 percent and 3...